Cited by 466Glioma Diagnosis and TreatmentLung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

Haas-Kogan, Daphne A., Prados, Michael D., Tihan, Tarik, Eberhard, David A., Jelluma, Nannette, Arvold, Nils D., Baumber, Rachel, Lamborn, Kathleen R., Kapadia, Ami, Malec, Mary, Berger, Mitchel S., Stokoe, David·2005·JNCI Journal of the National Cancer Institute

DOI 10.1093/jnci/dji161

Open this paper in CoChat — free account

Abstract

BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (also known as Tarceva or OSI-774) has shown promising response rates in malignant gliomas. We investigated the association between expression of EGFR and downstream signaling components and the response of malignant gliomas to erlotinib in a phase I trial of erlotinib administered either alone or with the alkylating agent temozolomide. METHODS: Expression of EGFR and ligand-independent EGFRvIII mutant proteins and of phosphorylated protein kinase B (PKB)/Akt in specimens from glioma patients were assessed by immunohistochemistry. EGFR gene amplification was evaluated by fluorescence in situ hybridization. Mutations in PTEN and EGFR were assessed by polymerase chain reaction amplification and sequencing. Response was evaluated by sequential magnetic resonance imaging every 2 months. The Cochran-Mantel-Haenzel test was used to assess associations between biomarker status and response. All statistical tests were two-sided. RESULTS: Of 41 glioma patients, eight responded to treatment. Response to erlotinib was associated with EGFR expression (P = .07) and EGFR amplification (P = .08). These associations were stronger and statistically significant among the 29 patients initially diagnosed with glioblastoma multiforme (P = .03 and P = .02, respectively). Among six responders with sufficient tumor tissue, none had EGFRvIII mutations. None of the 22 tumors with high levels of phosphorylated PKB/Akt responded to erlotinib treatment, whereas eight of the 18 tumors with low levels of phosphorylated PKB/Akt responded to erlotinib treatment (P < .001). The level of phosphorylated PKB/Akt was also associated with time to progression (P < .001). CONCLUSIONS: Among glioma patients, those with glioblastoma multiforme tumors who have high levels of EGFR expression and low levels of phosphorylated PKB/Akt had better response to erlotinib treatment than those with low levels of EGFR expression and high levels of phosphorylated PKB/Akt.

Integrity signals

Registry

Crossref · 10.1093/jnci/dji161

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,695
EGFR and cancer prognosis.
Nicholson, R., Gee, J., & Harper, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,132
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J. M., & Baselga, J. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,257
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 548
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Moasser, M. M., Basso, A., Averbuch, S. D., & Rosen, N. X. (2001) · PubMed · Cited by 508
Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991
Davis, F. G., Freels, S. A., Grutsch, J. F., Barlas, S., & Brem, S. S. (1998) · Journal of neurosurgery · doi:10.3171/jns.1998.88.1.0001 · Cited by 481
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
Bianco, R., Shin, I., Ritter, C. A., Yakes, F. M., Basso, A., Rosen, N. X., Tsurutani, J., Dennis, P. A., Mills, G. B., & Arteaga, C. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206388 · Cited by 449
Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer
Cappuzzo, F., Magrini, E., Ceresoli, G. L., Bartolini, S., Rossi, E., Ludovini, V., Gregorc, V., Ligorio, C., Cancellieri, A., Damiani, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh217 · Cited by 357
AKT Activity Determines Sensitivity to Mammalian Target of Rapamycin (mTOR) Inhibitors by Regulating Cyclin D1 and c-myc Expression
Gera, J., Mellinghoff, I. K., Shi, Y., Rettig, M. B., Tran, C., Hsu, J.-H., Sawyers, C. L., & Lichtenstein, A. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309999200 · Cited by 335
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat, M. L., Kruyt, F. A. E., Rodríguez, J. A., & Giaccone, G. (2003) · PubMed · Cited by 327
EGF mutant receptor vIII as a molecular target in cancer therapy.
Kuan, C., Wikstrand, C. J., & Bigner, D. D. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080083 · Cited by 325
Phosphorylation of Akt (Ser473) is an Excellent Predictor of Poor Clinical Outcome in Prostate Cancer
Kreisberg, J. I., Malik, S. N., Prihoda, T. J., Bedolla, R. G., Troyer, D. A., Kreisberg, S. H., & Ghosh, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0272 · Cited by 324
Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor
Moscatello, D. K., Holgado-Madruga, M., Emlet, D. R., Montgomery, B., & Wong, A. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.200 · Cited by 305
Determinants of Rapamycin Sensitivity in Breast Cancer Cells
Noh, W.-C., Mondesire, W. H., Peng, J., Jian, W., Zhang, H., Dong, J., Mills, G. B., Hung, M., & Meric‐Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0043 · Cited by 282
Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC
Cappuzzo, F., Gregorc, V., Rossi, E., Cancellieri, A., Magrini, E., Paties, C. T., Ceresoli, G. L., Lombardo, L., Bartolini, S., Calandri, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.039 · Cited by 211
Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product.
Kim, H., Sierke, S. L., & Koland, J. G. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31455-2 · Cited by 197
Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.
Bredel, M., If, P., Rl, H., & Cd, J. (1999) · PubMed · Cited by 190
Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.
Ermoian, R. P., Furniss, C. S., Lamborn, K. R., Basila, D., Berger, M. S., GOTTSCHALK, A. R., Nicholas, M. K., Stokoe, D., & Haas-Kogan, D. A. (2002) · PubMed · Cited by 177
Opportunities and challenges in the development of kinase inhibitor therapy for cancerPreprint
Sawyers, C. L. (2003) · Genes & Development · doi:10.1101/gad.1152403 · Cited by 170
Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications
Justin, S. S. (2000) · Frontiers in bioscience · doi:10.2741/smith · Cited by 160
Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme
Learn, C. A., Hartzell, T. L., Wikstrand, C. J., Archer, G. E., Rich, J. N., Friedman, A. H., Friedman, H. S., Bigner, D. D., & Sampson, J. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0521 · Cited by 158
Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer
Reissmann, P. T., Koga, H., Figlin, R. A., Holmes, E. C., & Slamon, D. J. (1999) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050243 · Cited by 118
Patterns of epidermal growth factor receptor amplification in malignant gliomas.
Sauter, G., MAEDA, T., Waldman, F. M., Davis, R. L., & Feuerstein, B. G. (1996) · Europe PMC (PubMed Central) · Cited by 112
EGF receptor amplification and expression in human brain tumours
Chaffanet, M., Chauvin, C., Lainé, M. G., Berger, F. R., Chedin, M., Rost, N., Nissou, M.-F., & Benabid, A. L. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90374-b · Cited by 104
Cytoplasmic Mislocalization of p27Kip1 Protein Is Associated with Constitutive Phosphorylation of Akt or Protein Kinase B and Poor Prognosis in Acute Myelogenous Leukemia
Min, Y. H., Cheong, J., Kim, J. Y., Eom, J.-I., Lee, S., Hahn, J. S., Ko, Y. W., & Lee, M. H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0174 · Cited by 96
O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone
Bailey, R., Kris, M. G., Wolf, M., Kay, A., Averbuch, S. D., Askaa, J., Janas, M. S., Schmidt, K., & Fukuoka, M. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)91900-3 · Cited by 95
33 Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma
Prados, M., Chang, S. M., Burton, E. M., Parney, I., Kapadia, A., Rabbitt, J. E., Page, M., Federoff, A., Kelley, S. K., & Fyfe, G. (2003) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(03)90067-x · Cited by 56
Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with genfinitib (ZD1839)
Rojo, F., Tabernero, J. M., Cutsem, E. V., Ohtsu, A., Albanell, J., Koizumi, W., Peeters, M., Averbuch, S. D., Gallagher, N. J., & Baselga, J. M. (2003) · Ghent University Academic Bibliography (Ghent University) · Cited by 25
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Thomas, M. (2003) · Cancer Nursing · doi:10.1097/00002820-200312001-00006 · Cited by 18
A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer
Glover, K. Y., Pérez-Soler, R., & Papadimitradopoulou, V. A. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.019 · Cited by 17
A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR
(2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80868-1 · Cited by 4

Research works printed but not linked: 2

Salz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc ASCO2001 (abstr); 20 : 7A .
Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc ASCO2002 (abstr); 21 : 504 .

Sorted by citations

Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J. A., Hann, B. C., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 993
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L. J., Yedjou, C. G., Hsu, H.-Y., Lin, L., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 897

See all 466

Authors: Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., Berger, M. S., & Stokoe, D.
Affiliations: University of California, San Francisco (US)
Corresponding author: Haas-Kogan, Daphne A.
ORCID: Haas-Kogan, Daphne A.
Prados, Michael D.
Jelluma, Nannette
Arvold, Nils D.
Baumber, Rachel
Berger, Mitchel S.
Stokoe, David
Venue: JNCI Journal of the National Cancer Institute
Publisher: Oxford University Press (OUP)
Published: 2005-06-15
Volume: 97
Issue: 12
Pages: 880-887
ISSN: 0027-8874 (ISSN-L)
1460-2105
DOI: 10.1093/jnci/dji161
OpenAlex: W2104743043
Cited by: 465
References: 37
Citations by year: 2026: 3 · 2025: 2 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 4 · 2020: 9 · 2019: 5 · 2018: 7 · 2017: 13 · 2016: 6 · 2015: 17 · 2014: 24 · 2013: 27 · 2012: 34
FWCI: 22.18
Type: journal article
Language: en
Open access: closed
Locations: JNCI Journal of the National Cancer Institute (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5m01rr000079-42)
National Cancer Institute (P50CA097257)
National Institute of Neurological Disorders and Stroke (P01NS042927, P01 NS42927)
National Center for Research Resources (M01 RR-00079)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: erlotinib, EGFR tyrosine kinase inhibitors, high-grade glioma, glioblastoma, EGFR amplification, EGFRvIII, Akt phosphorylation, Akt, temozolomide, predictive biomarkers, treatment response, PTEN mutation, time to progression
MeSH terms: Erlotinib Hydrochloride, Temozolomide, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Dacarbazine, Drug Administration Schedule, Female, Glioma, Humans, Immunohistochemistry, Male, Middle Aged, Mutation, Phosphoric Monoester Hydrolases, Phosphorylation, Proto-Oncogene Proteins, Quinazolines, Supratentorial Neoplasms, Protein Serine-Threonine Kinases, In Situ Hybridization, Fluorescence, Drug Resistance, Neoplasm, Area Under Curve, Tumor Suppressor Proteins, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks